What are the best treatments for Beckwith-Wiedemann Syndrome?

TL;DR: There is no single "cure" for Beckwith-Wiedemann Syndrome (BWS); instead, treatment is highly individualized, focusing on managing specific clinical manifestations and rigorous tumor surveillance. Care for Beckwith-Wiedemann Syndrome is multidisciplinary, requiring regular screenings for overgrowth-related complications and surgical intervention for structural issues like macroglossia or abdominal wall defects.

How is Beckwith-Wiedemann Syndrome managed clinically?

Because Beckwith-Wiedemann Syndrome is a spectrum disorder, management must be tailored to the specific needs of the child. The primary medical focus is not just on current symptoms, but on proactive prevention. Patients with Beckwith-Wiedemann Syndrome have an increased risk of childhood cancers, primarily Wilms tumor and hepatoblastoma. Therefore, the cornerstone of treatment is a standardized tumor surveillance protocol, which typically includes abdominal ultrasounds every three months until at least age eight and regular monitoring of serum alpha-fetoprotein (AFP) levels.

What are the primary surgical and non-pharmacological interventions?

Many children born with Beckwith-Wiedemann Syndrome require surgical correction for structural abnormalities. These interventions are highly personalized based on the severity of the presentation. Common non-pharmacological and surgical approaches include:

• Surgical correction of abdominal wall defects: Procedures to repair omphalocele, umbilical hernia, or diastasis recti.


• Macroglossia management: Surgical tongue reduction (glossectomy) may be considered if the enlarged tongue interferes with breathing, speech development, or dental alignment.


• Physical and occupational therapy: Essential for children who experience developmental delays or motor skill challenges associated with Beckwith-Wiedemann Syndrome.


• Speech therapy: Often utilized if macroglossia or structural dental issues impact speech articulation.

Which specialists should be on the care team?

Managing Beckwith-Wiedemann Syndrome requires a coordinated, multidisciplinary care team. Because the condition affects multiple organ systems, the following specialists are typically involved:

1. Clinical Geneticist: To confirm the diagnosis through molecular testing and provide family counseling.


2. Pediatric Oncologist: To oversee the tumor surveillance schedule.


3. Pediatric Surgeon: For the management of abdominal wall defects or macroglossia.


4. Endocrinologist: To monitor for hypoglycemia, which can occur in the neonatal period for patients with Beckwith-Wiedemann Syndrome.


5. Speech and Physical Therapists: To support developmental milestones.

Are there medications or emerging treatments for Beckwith-Wiedemann Syndrome?

There are no specific pharmaceutical "cures" for the underlying genetic mechanisms of Beckwith-Wiedemann Syndrome. Medications are used strictly to manage secondary complications. For example, if a neonate experiences hyperinsulinism-induced hypoglycemia, a clinician may prescribe diazoxide (Proglycem) to stabilize blood glucose levels. Research is ongoing into the epigenetic mechanisms of the 11p15.5 region, but currently, no gene-editing or epigenetic-modifying therapies are available in clinical practice. The 241 members of the DiseaseMaps community often highlight the importance of finding centers of excellence that specialize in these complex, multi-system management protocols.

Next steps

• Consult with a board-certified clinical geneticist to ensure a comprehensive surveillance plan is in place.


• Join the DiseaseMaps community to connect with other families navigating the complexities of Beckwith-Wiedemann Syndrome.


• Keep a detailed medical binder tracking all ultrasound results and specialist consultations.


• Visit the BWS Support Group or similar patient advocacy organizations for updated clinical trial information.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare team for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Beckwith-Wiedemann Syndrome.


• Orphanet: Beckwith-Wiedemann Syndrome (ORPHA:107).


• OMIM (Online Mendelian Inheritance in Man): #130650.


• American Association for Cancer Research (AACR) surveillance guidelines for Beckwith-Wiedemann Syndrome.